Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Anavo Therapeutics BV
Netherlands
- Leiden, South Holland
- 04/05/2023
- Seed
- $9,406,482
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
- Industry Biotechnology Research
- Website https://www.anavotx.com/
- LinkedIn https://www.linkedin.com/company/anavo-therapeutics-bv/
Related People
Birgit ZechFounder
Germany -
ND
• 20 years working experience in Biotech, 15+ years in Business Development
• In depth knowledge of the pharmaceutical and biotech industry
• Excellent track record in deal making and fundraising
• Strong network to leading Pharma and Biotech companies, significant partnering experience in EP, US and JP
• Over 5 years experience in IP management
• Strong background in chemistry (small molecules, kinase inhibitors, protein modeling) and biology (antibodies, next generation scaffolds)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)